Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s blockbuster Dupixent. Last year, BMS reported a phase 3 trial in eosinophilic ...
Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback